A report from the International Stand Up to Cancer/American Association for Cancer Research Prostate Cancer/Prostate Cancer Foundation Team (SU2C-PCF) showed genetic alterations of DDR genes in 23% of 150 metastatic biopsy samples [45]. This evidence concerns the gene DDR1 and prostate cancer.